Table 1.
Time trends and macro-areas of consumption (DDD/1000 inhabitants per day) of Alzheimer’s disease drugs, by therapeutic category and substance in the period 2018–2020 (65 + years)
| ADDs | 2018 | 2019 | 2020 | ∆ % 19–20 | CAGR % 18–20 |
|---|---|---|---|---|---|
| AChEIs | 5.44 | 5.35 | 5.12 | − 4.3 | − 3.0 |
| Rivastigmine | 2.17 | 2.06 | 1.90 | − 7.8 | − 6.5 |
| Galantamine | 0.16 | 0.14 | 0.12 | − 11.8 | − 12.8 |
| Donepezil | 3.10 | 3.15 | 3.10 | − 1.7 | − 0.1 |
| Other ADDs | |||||
| Memantine | 3.67 | 3.81 | 3.86 | 1.3 | 2.6 |
| Italy | 9.11 | 9.16* | 8.96 | − 2.2 | − 0.8 |
| North | 8.13 | 8.28 | 8.05 | − 2.8 | − 0.5 |
| Centre | 10.85 | 10.73 | 10.75 | 0.2 | − 0.5 |
| South and islands | 9.46 | 9.48 | 9.18 | − 3.2 | − 1.5 |
*From sensitivity analysis including only prevalent users: 7.92 DDD/1000 inhab. per day
Bold indicates the overall data for Italy